Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2.

1. Renal haemodynamics, lithium and sodium clearance were measured in 14 patients treated with recombinant interleukin-2 for metastatic renal cell carcinoma. 2. Patients were studied before and after 72 h of continuous intravenous infusion of recombinant interleukin-2 (18x10(6) i.u..24 h-1.m-2) and 48 h post therapy. Cardiac output was measured by impedance cardiography. Effective renal plasma flow and glomerular filtration rate were determined by the renal clearances of 131I-hippuran and 99mTc-diethylenetriaminepenta-acetic acid (DTPA) respectively. Renal clearance of lithium (CLi) was used as an index of proximal tubular outflow. 3. Treatment caused a transient decrease in mean arterial blood pressure and systemic vascular resistance, but cardiac output remained unchanged. Renal blood flow decreased and renal vascular resistance increased during and after treatment. Sodium clearance decreased from 1.10 (0.63/1.19) ml/min to 0.17 (0.18/0.32) ml/min (P=0.003). Glomerular filtration rate remained unchanged, whereas the median CLi decreased from 26 (17/32) ml/min to 17 (10/21) ml/min (P=0.008). Calculated absolute proximal reabsorption rate of water increased from 63 (40/69) ml/min to 71 (47/82) ml/min (P=0.04). The urinary excretion rate of thromboxane B2 and the ratio between excretion rates of thromboxane B2 and 6-keto-prostaglandin-F1alpha increased by 98% (P=0.022) and 175% (P=0.022) respectively. 4. The study suggests a specific recombinant interleukin-2-induced renal vasoconstrictor effect. Changes in renal prostaglandin synthesis may contribute to the decrease in renal blood flow. The lithium clearance data suggest that an increased proximal tubular reabsorption rate may contribute to the decreased sodium clearance during recombinant interleukin-2 treatment.

[1]  P. Leyssac,et al.  Effect of dietary sodium content on renal handling of lithium , 1986, Pflügers Archiv.

[2]  D. G. Shirley,et al.  The validity of lithium clearance as an index of sodium and water delivery from the proximal tubules. , 1997, Nephron.

[3]  P. Lehtovirta,et al.  Effect of interleukin 2 on urinary excretion of degradation products of prostacyclin and thromboxane A2 in patients with ovarian cancer. , 1995, British Journal of Cancer.

[4]  S. Walter,et al.  Evaluation of the lithium clearance method: direct analysis of tubular lithium handling by micropuncture. , 1995, Kidney international.

[5]  J. Bernheim,et al.  Increased thromboxane mediates the adverse renal effects of interleukin-2 in rats. , 1994, Journal of the American Society of Nephrology : JASN.

[6]  D. Kohan.  Role of endothelin and tumour necrosis factor in the renal response to sepsis. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  S. Strandgaard,et al.  Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. , 1993, Clinical science.

[8]  P. Ponce,et al.  Renal toxicity mediated by continuous infusion of recombinant interleukin-2. , 1993, Nephron.

[9]  S. Heys,et al.  Lithium clearance measurements during recombinant interleukin 2 treatment: tubular dysfunction in man. , 1993, Renal failure.

[10]  A. Cumming,et al.  Hemodynamic, renal, and hormonal actions of aprotinin in an ovine model of septic shock , 1992, Critical care medicine.

[11]  D. Morel,et al.  Sequential changes in renal oxygen consumption and sodium transport during hyperdynamic sepsis in sheep. , 1992, The American journal of physiology.

[12]  G. Hermann,et al.  Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Allaouchiche,et al.  Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. , 1991, Kidney international.

[14]  L. Kobzik,et al.  Interleukin‐2 Induces Early Multisystem Organ Edema Mediated by Neutrophils , 1991, Annals of surgery.

[15]  D. Feinfeld,et al.  Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Thomsen.  Lithium clearance as a measure of sodium and water delivery from the proximal tubules. , 1990, Kidney international. Supplement.

[17]  J. Atherton,et al.  Lithium clearance in healthy humans: effects of sodium intake and diuretics. , 1990, Kidney international. Supplement.

[18]  G. Dibona.  Role of renal nerves in volume homeostasis. , 1990, Acta physiologica Scandinavica. Supplementum.

[19]  P. Leyssac,et al.  Intrarenal control of GFR, with special reference to proximal reabsorption. , 1990, Acta physiologica Scandinavica. Supplementum.

[20]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[21]  N. Bruun,et al.  Unchanged lithium clearance during acute amiloride treatment in sodium-depleted man. , 1989, Scandinavian journal of clinical and laboratory investigation.

[22]  R. Fisher,et al.  A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Dibona.  Update on renal neurology: role of the renal nerves in formation of edema. , 1989, Mayo Clinic proceedings.

[24]  R. Fisher,et al.  Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Dibona.  Neural control of renal tubular solute and water transport. , 1989, Mineral and electrolyte metabolism.

[26]  F. Ognibene,et al.  Cardiorespiratory effects of immunotherapy with interleukin-2. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Fisher,et al.  The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, Annals of internal medicine.

[28]  N. V. Raghavaiah.  Renal, Volume, and Hormonal Changes During Therapeutic Administration of Recombinant Interleukin-2 in Man , 1988 .

[29]  F. Ognibene,et al.  Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. , 1988, Chest.

[30]  W. M. Linehan,et al.  Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. , 1988, Clinical nephrology.

[31]  E. J. Mees,et al.  Lithium clearance during variations in sodium intake in man: effects of sodium restriction and amiloride , 1988, European journal of clinical investigation.

[32]  B. Kennedy,et al.  Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. , 1988, The American journal of medicine.

[33]  W C Shoemaker,et al.  Multicomponent noninvasive physiologic monitoring of circulatory function. , 1988, Critical care medicine.

[34]  S. Steinberg,et al.  Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. , 1987, Annals of internal medicine.

[35]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[36]  S. Rosenberg,et al.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. , 1986, Journal of immunology.

[37]  M. Lifschitz,et al.  Effect of prostaglandins on renal salt and water excretion. , 1986, The American journal of medicine.

[38]  A. Morrison.  Biochemistry and pharmacology of renal arachidonic acid metabolism. , 1986, The American journal of medicine.

[39]  M. Epstein,et al.  Renal prostaglandins and the control of renal function in liver disease. , 1986, The American journal of medicine.

[40]  M. Dunn,et al.  Eicosanoids in experimental and human renal disease. , 1986, The American journal of medicine.

[41]  P. Leyssac,et al.  Acute effects of various diuretics on lithium clearance. Studies in rats on medium and low sodium diet. , 1986, Renal physiology.

[42]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[43]  J P Kriss,et al.  Limitations of creatinine as a filtration marker in glomerulopathic patients. , 1985, Kidney international.

[44]  M Rehling,et al.  Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. , 1984, Clinical science.

[45]  D M Clive,et al.  Renal syndromes associated with nonsteroidal antiinflammatory drugs. , 1984, The New England journal of medicine.

[46]  B. Brenner,et al.  The renal circulations. , 1978, Hospital practice.

[47]  J. Bröchner-Mortensen,et al.  Selection of routine method for determination of glomerular filtration rate in adult patients. , 1976, Scandinavian journal of clinical and laboratory investigation.